Doctronic announced it has raised $40 million in a Series B funding round co-led by Abstract and Lightspeed Venture Partners, with participation from Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. The financing, the company’s third round in less than 12 months, brings total funding to more than $65 million.
The announcement follows a period of rapid growth for the New York-based company. In under six months since its Series A, Doctronic reported 15× growth to eight-figure annualized revenue, while nearly tripling its repeat patient rate. The platform now serves more than 300,000 unique weekly users and continues to expand its direct-to-consumer and enterprise healthcare partnerships.
Founded in 2023 by Adam Oskowitz and Matt Pavelle, Doctronic has built an AI-powered clinical system designed to autonomously evaluate symptoms, generate diagnoses, and guide treatment decisions. The platform operates as both a consumer-facing healthcare service and an infrastructure layer for health systems, payers, and employers.
A major milestone came in December 2025, when Doctronic became the first AI-native platform authorized to autonomously renew prescriptions in the United States under Utah’s AI Learning Lab regulatory sandbox. The system currently supports prescription renewals across 190 medications and includes safeguards such as continuous monitoring and automatic escalation to licensed physicians for complex cases.
Doctronic operates its own clinical practice, licensed across all 50 states, and integrates with national health data networks, including QHIN/TEFCA, Surescripts, and First Databank, to access patient records, medication histories, and drug interaction data. The company’s platform uses a multi-agent AI architecture to conduct structured clinical reasoning while maintaining physician oversight where required.
The company said the new capital will be used to expand partnerships with hospital systems, academic medical centers, digital health platforms, and payers, while also supporting a push into pediatric care, where demand significantly exceeds available supply. Doctronic is also in discussions with regulators in additional states and international markets to expand its AI-driven prescription capabilities.
Doctronic positions itself as a new model for delivering primary care at scale, offering 24/7 access to AI-driven consultations alongside optional telehealth visits with licensed physicians. The company emphasizes its ability to take responsibility for clinical outcomes rather than simply providing informational support, a distinction it sees as critical in the evolution of AI in healthcare.
KEY QUOTES:
“Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale. The Utah program validated their clinical rigor. The revenue growth validated market demand. What sets them apart is the courage to take responsibility for outcomes, not just provide information. That’s the future of healthcare.”
Ramtin Naimi, Partner at Abstract
“The combination of user traction, revenue momentum, and partnerships with major health systems makes it clear: Doctronic is the breakout leader in AI-powered medicine. They’ve built autonomous AI that integrates safely into real clinical workflows and brings in real patient context, uniquely delivering on the treatment through triage vision at an unmatched scale.”
Faraz Fatemi, Partner at Lightspeed Venture Partners
“This round reflects Doctronic’s category leadership: unmatched consumer scale and a best-in-class AI clinical model. Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network. Payers see us as unlimited primary care at predictable cost. This round lets us push further into academic medical centers, digital health platforms, and payers, while continuing to serve millions of consumers directly.”
Matt Pavelle, Co-CEO and Co-Founder of Doctronic
“We’re not just faster and cheaper than traditional care, we’re more thorough. Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour. The 99.2% treatment alignment rate isn’t theoretical, it’s from real patients in real clinical scenarios. But what I’m most proud of is retention. Since the Series A, monthly repeat physician visits have nearly tripled. Patients aren’t just trying us, they’re coming back.”
Adam Oskowitz, Co-Founder of Doctronic
